Journal
Journal of Thoracic and Cardiovascular Surgery
Publication Date
3-1-2023
Volume
165
Issue
3
First Page
828
Last Page
839.e5
Document Type
Open Access Publication
DOI
10.1016/j.jtcvs.2022.10.007
Rights and Permissions
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 Mar;165(3):828-839.e5. doi: 10.1016/j.jtcvs.2022.10.007. Copyright 2022 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Rusch, Valerie W; Patterson, G Alexander; Waqar, Salama N; and et al., "Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer." Journal of Thoracic and Cardiovascular Surgery. 165, 3. 828 - 839.e5. (2023).
https://digitalcommons.wustl.edu/oa_4/2708
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
